Composition and method for treating inflammatory disorders
AssigneeWyeth
InventorsKenneth Jacobs, Debra D. Pittman, Lynette Fouser, Vikki Spaulding, Dejun Xuan
Life of this patent
Estimating the term…
Abstract
Inhibitors of IL-22 are disclosed as well as pharmaceutical compositions and methods of using same. The inhibitors include IL-22 antibodies and are useful for treating inflammatory disorders.
Claims33
An antibody which immunologically reacts with an IL 22 protein.
A pharmaceutical composition comprising an IL-22 antibody which immunologically reacts with an IL 22 protein comprising the amino acid sequence of SEQ ID NO:2 and a pharmaceutical carrier.
A method of treating a pathological condition in a subject associated with IL-22 activity comprising administering an effective amount of an agent that inhibits levels of IL-22 activity, thereby treating said pathological condition.
A method of treating symptoms associated with arthritis, said method comprising administering to a subject in need thereof a therapeutically effective amount of an IL-22 antibody.
A method of enhancing a subject's immune response to an antigen, comprising the steps of administering to said subject an immunogenic amount of said antigen and an immunogenicity-augmenting amount of IL-22 in concurrent or sequential combination with said antigen such that said subject's immune response is enhanced.
A method of treating a pathological condition in a subject in need of IL-22 modulation, comprising administering an effective amount of an agent that modulates IL-22 activity, such that the pathological condition in said subject is treated.
A method of treating inflammatory pathology in the kidney of a subject comprising administering an effective amount of an agent that modulates IL-22 activity, such that said inflammatory pathology of said subject is treated.
A method of treating cancer in a subject comprising administering an effective amount of an agent that modulates IL-22 activity, such that cancer is treated.
A method of remodeling kidney tissue comprising administering an effective amount of an agent that modulates IL-22 activity such that remodeling of kidney tissue occurs.
Dependencies are inferred from the claim text.